Hcw Biologics INC. 8-K Filing
Ticker: HCWB · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1828673
Sentiment: neutral
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-11-18 07:30:26
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar
Filing Documents
- hcwb-20251117.htm (8-K) — 44KB
- hcwb-ex99_1.htm (EX-99.1) — 30KB
- img90053791_0.jpg (GRAPHIC) — 134KB
- 0001193125-25-285325.txt ( ) — 369KB
- hcwb-20251117.xsd (EX-101.SCH) — 24KB
- hcwb-20251117_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 18, 2025, HCW Biologics Inc. (the "Company") issued a press release announcing that the first patient was dosed in a Company-sponsored, multi-center Phase 1 clinical trial to evaluate the Company's lead product candidate, HCW9302, in patients with an autoimmune disorder. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated November 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: November 18, 2025 By: /s/ Hing C. Wong Hing C. Wong, Founder and Chief Executive Officer